Nantahala reports 9.99% Edesa Biotech (NASDAQ: EDSA) stake

Rhea-AI Filing Summary

Nantahala Capital Management and its principals reported a significant ownership position in Edesa Biotech. As of December 31, 2025, they may be deemed to beneficially own 855,583 common shares, representing 9.99% of the outstanding class. This total includes 230,583 shares that can be acquired within sixty days through convertible securities. Voting and dispositive power over all reported shares is shared among Nantahala, Wilmot B. Harkey, and Daniel Mack, with no sole authority. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Edesa Biotech.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

EDESA BIOTECH, INC.

(Name of Issuer)

Common Shares, without par value

(Title of Class of Securities)

27966L306

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 27966L306

1

Names of Reporting Persons

Nantahala Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 855,583.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 855,583.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

855,583.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 27966L306

1

Names of Reporting Persons

Wilmot B. Harkey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 855,583.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 855,583.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

855,583.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 27966L306

1

Names of Reporting Persons

Daniel Mack

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 855,583.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 855,583.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

855,583.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: EDESA BIOTECH, INC.
(b)	Address of issuer's principal executive offices: 100 SPY COURT ON, Canada, ONTARIO, CANADA, L3R 5H6
Item 2.
(a)	Name of person filing: (1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
(b)	Address or principal business office or, if none, residence: 130 Main St. 2nd Floor, New Canaan, Connecticut 06840
(c)	Citizenship: (1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
(d)	Title of class of securities: Common Shares, without par value
(e)	CUSIP No.: 27966L306
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of December 31, 2025, Nantahala may be deemed to be the beneficial owner of 855,583 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 855,583 Shares includes 230,583 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of convertible securities.
(b)	Percent of class: As of December 31, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 9.99% (2) Wilmot B. Harkey: 9.99% (3) Daniel Mack: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
	(ii) Shared power to vote or to direct the vote: (1) Nantahala Capital Management, LLC ("Nantahala") : 855,583 Shares. (2) Wilmot B. Harkey: 855,583 Shares. (3) Daniel Mack: 855,583 Shares.
	(iii) Sole power to dispose or to direct the disposition of: (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
	(iv) Shared power to dispose or to direct the disposition of: (1) Nantahala Capital Management, LLC ("Nantahala") : 855,583 Shares. (2) Wilmot B. Harkey: 855,583 Shares. (3) Daniel Mack: 855,583 Shares.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nantahala Capital Management, LLC

Signature:	/s/ Taki Vasilakis
Name/Title:	Taki Vasilakis / Chief Compliance Officer
Date:	02/13/2026

Wilmot B. Harkey

Signature:	/s/ Wilmot B. Harkey
Name/Title:	Wilmot B. Harkey
Date:	02/13/2026

Daniel Mack

Signature:	/s/ Daniel Mack
Name/Title:	Daniel Mack
Date:	02/13/2026

FAQ

What ownership stake in Edesa Biotech (EDSA) does Nantahala report?

Nantahala and its principals report beneficial ownership of 855,583 Edesa Biotech common shares, representing 9.99% of the outstanding class as of December 31, 2025. This makes them a significant institutional shareholder under U.S. disclosure rules.

How is Nantahala’s 855,583-share Edesa Biotech (EDSA) position structured?

The 855,583 reported shares include 230,583 Edesa Biotech common shares that may be acquired within sixty days through convertible securities. The remainder is held by funds and separately managed accounts that Nantahala advises and controls.

Who shares voting and dispositive power over Edesa Biotech (EDSA) shares?

Nantahala Capital Management, Wilmot B. Harkey, and Daniel Mack each report zero sole voting or dispositive power, but shared power over 855,583 Edesa Biotech shares. This means decisions on voting and sales are jointly controlled for the reported position.

Is Nantahala’s Edesa Biotech (EDSA) stake a passive investment?

The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Edesa Biotech. This language is characteristic of a passive Schedule 13G-type ownership position.

What role does Blackwell Partners LLC - Series A have in Edesa Biotech (EDSA)?

Blackwell Partners LLC - Series A, a fund advised by Nantahala, has the right to receive or direct dividends and sale proceeds from more than five percent of Edesa Biotech’s outstanding common shares that are beneficially owned and reported by Nantahala.

Why are Wilmot B. Harkey and Daniel Mack listed on the Edesa Biotech (EDSA) filing?

Wilmot B. Harkey and Daniel Mack are managing members of Nantahala and are treated as control persons for the Edesa Biotech position. Each may be deemed to beneficially own 855,583 shares, or 9.99% of the class, through Nantahala-managed funds and accounts.